FDA Expert Witness Services
Leverage The Most Trusted FDA Experts in the World
When litigation hinges on FDA compliance and regulatory interpretation, credibility and clarity are everything. ProPharma's expert witness consulting services deliver unparalleled insight, strategic support, and courtroom-ready testimony from the largest team of former FDA and senior industry professionals in the world. Whether you're involved in a business dispute, product liability case, patent issue, or pursuing damages in a regulatory dispute, we provide expert guidance rooted in real-world FDA experience and scientific rigor.
Comprehensive FDA Expertise Across Product Areas
We support legal teams and life sciences clients in a wide range of matters involving FDA-regulated products, including:
- FDA Enforcement Actions: 483 observations, warning letters, consent decrees, import detentions, and recalls
- Product Development & Approval Pathways: NDAs, ANDAs, 510(k)s, PMAs, De Novo submissions, and combination product strategies
- Pharmaceutical, Biotech & Device Litigation: Adulteration, misbranding, product liability, and regulatory negligence claims
- Advertising & Promotional Compliance: OPDP compliance, off-label promotion, fair balance, and substantiation disputes
- Clinical Trials & GCP Compliance: Site inspections, data integrity, informed consent violations, protocol deviations
- Manufacturing & Quality Systems: cGMP/QSR deficiencies, supplier quality, CAPAs, MDRs, and risk management gaps
Our team of FDA Expert Witness Consultants brings an insider’s perspective to every case—identifying gaps, explaining regulatory expectations, and anticipating FDA interpretations that can sway outcomes.
Why Choose ProPharma's Team of FDA Expert Witness Consultants?
Our expert team sets the global standard for FDA-related litigation support. We offer:
Unmatched Regulatory Expertise
Our roster is comprised of more former FDA employees than any other consulting firm—including former reviewers, inspectors, compliance officers, and division directors who understand FDA expectations from the inside out. Our bench also consists of many senior industry executives, with an impressive breadth and depth of scientific and regulatory expertise.
Scientific and Strategic Depth
In addition to regulatory backgrounds, our experts are PhD/MD scientists, clinical trialists, engineers, and manufacturing specialists with deep domain knowledge across the product lifecycle.
Credible, Court Tested Authority
We are the most trusted FDA expert witnesses in the world, with extensive experience supporting clients in federal and state courts, arbitration panels, and regulatory hearings.
Clarity That Persuades
Our consultants translate complex regulatory and scientific concepts into clear, defensible testimony that resonates with judges, juries, and legal counsel alike.
Strategic Support at Every Stage of Litigation
Whether you're building your case or preparing for trial, we serve as a strategic partner throughout the legal process:
- Early Case Assessment: We help legal teams evaluate regulatory strengths and weaknesses and refine case strategy
- Expert Reports & Declarations: Our experts craft detailed, objective reports that withstand scrutiny and communicate clearly
- Deposition & Trial Testimony: Our seasoned experts are skilled at delivering confident, credible testimony that holds up under cross-examination
- Rebuttal & Opposing Expert Analysis: We review and critique the opinions and assumptions of opposing FDA experts to help you anticipate challenges and build counterpoints
From technical assessments to high-stakes testimony, ProPharma’s expert witness consultants deliver the insight and authority your case needs.
Who We Serve
Our FDA expert witness services are trusted by top-tier clients around the world, including:
- Law Firms representing pharmaceutical, medical device, biotechnology, and diagnostics companies in civil, criminal, and regulatory matters
- Life Sciences Companies facing litigation, government investigations, product recalls, or shareholder actions
- Insurance Providers & Risk Managers seeking defensible analysis of regulatory compliance and product safety claims
- Litigation Support Firms in need of high-caliber expert evaluation, documentation review, and testimony
When regulatory credibility is on the line, leading firms rely on our unparalleled FDA knowledge and litigation support capabilities.
Partner with the World's Leading FDA Experts
With the largest team of former FDA professionals and globally recognized scientific and regulatory expertise, we are the trusted authority for FDA expert witness support. Our consultants have shaped policy, led inspections, reviewed product submissions, and now help clients succeed in high-stakes litigation.
ProPharma: The World's Leading Regulatory Consultancy
Contact us today to discuss your case and learn how our experts can strengthen your legal strategy with insight that only firsthand FDA experience can provide.
News & Insights
March 19, 2026
Operational Excellence in Global Clinical Research: Why Culture Drives Performan...
Discover why operational excellence in global clinical research hinges on culture, not just metrics. Learn how leadership, trust, and collaboration drive consistent quality outcomes.
March 17, 2026
Skinny Labels Under the Microscope: What Hikma v. Amarin Means for Drug Develope...
The Supreme Court's review of Hikma v. Amarin could reshape the legal and regulatory landscape for skinny labels and Section viii carve-outs.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
December 11, 2025
ProPharma Expands Operations with New Office in Hyderabad
ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
March 16, 2026
CMO Compass & Supply Chain Management
ProPharma provides comprehensive supply chain management and consulting services to support the efficient delivery of clinical trial materials throughout the product lifecycle. Using its CMO Compass®...
March 13, 2026
Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partne...
A mid-sized biotechnology company operating in the EU faced critical pharmacovigilance (PV) compliance findings following an inspection by the European Medicines Agency and Medicines and Healthcare...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
March 13, 2026
Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partne...
A mid-sized biotechnology company operating in the EU faced critical pharmacovigilance (PV) compliance findings following an inspection by the European Medicines Agency and Medicines and Healthcare...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...